Halozyme announces Takeda receives approval for HYQVIA by MHLW

Halozyme Therapeutics (HALO) announced that Takeda (TAK) received regulatory approval for HYQVIA by the Japanese Ministry of Health, Labour and Welfare, MHLW, for patients with agammaglobulinemia or hypogammaglobulinemia, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency, PID, or secondary immunodeficiency, SID. “We are very pleased that patients in Japan with agammaglobulinemia or hypogammaglobulinemia can now access HYQVIA, which represents the first and only subcutaneous immunoglobulin therapy that offers the potential of a reduced dosing frequency,” said Dr. Helen Torley, president and chief executive officer of Halozyme. “We appreciate the opportunity to continue to provide patients with more flexible treatment options with our innovative drug delivery technology.”